Drug Trial Radar · NCT03247686
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Feb 1, 2017
Primary completion
Jul 15, 2018
Study completion Aug 1, 2019
Sponsor
- Lead sponsor
- Resolve TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- University Hospital Birmingham; Newcastle-upon-Tyne Hospitals NHS Trust
- First posted
- Aug 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study will examine the role of circulating RNA complexed with autoantibodies and immune complexes and its role in activation of inflammatory pathways in patients with primary Sjogren's syndrome. The study will be conducted in a subset of Sjogren's patients who have elevated levels of autoantibodies and a pattern of elevated interferon-stimulated gene expression in blood cells. A number of biochemical and clinical parameters will be analyzed to determine the potential therapeutic utility of nuclease therapy in Sjogren's syndrome.
Conditions
- Sjogren's Syndrome
Interventions
RSLV-132Drug
RNase Fc fusion protein
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood Cell Gene ExpressionTime frame: Day 1 and Day 99
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University Hospitals Birmingham
Birmingham, Edgbaston, United Kingdom
Newcastle upon Tyne Hospitals
Newcastle upon Tyne, Gosforth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.